Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBITDA (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBITDA for 7 consecutive years, with -$86.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA fell 16.87% to -$86.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$308.1 million, a 37.05% decrease, with the full-year FY2025 number at -$308.1 million, down 37.05% from a year prior.
  • EBITDA was -$86.7 million for Q4 2025 at Kymera Therapeutics, down from -$81.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$12.5 million in Q4 2023 to a low of -$86.7 million in Q4 2025.
  • A 5-year average of -$46.8 million and a median of -$41.7 million in 2022 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: skyrocketed 63.22% in 2023, then crashed 494.77% in 2024.
  • Kymera Therapeutics' EBITDA stood at -$34.4 million in 2021, then grew by 1.49% to -$33.9 million in 2022, then skyrocketed by 63.22% to -$12.5 million in 2023, then plummeted by 494.77% to -$74.2 million in 2024, then fell by 16.87% to -$86.7 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EBITDA are -$86.7 million (Q4 2025), -$81.0 million (Q3 2025), and -$76.3 million (Q2 2025).